YPSOMED HOLDING AG Ypsomed - Investor Fact Sheet 1
Investor Fact Sheet
First half-year 2023/24
(Unaudited Swiss GAAP FER figures) | Half-year | Half-year | ||||
in thousand CHF | 2023/24 | in % | 2022/23 | in % | Change | in % |
Sales of goods and services group | 255 390 | 100.0 % | 244 244 | 100.0 % | 11 145 | 4.6 % |
thereof continued business group | 255 390 | 205 856 | 49 534 | 24.1 % | ||
Ypsomed Delivery Systems | 176 527 | 69.1 % | 143 728 | 58.8 % | 32 799 | 22.8 % |
Ypsomed Diabetes Care | 72 585 | 28.4 % | 92 013 | 37.7 % | - 19 428 | - 21.1 % |
thereof continued business YDC | 72 585 | 53 625 | 18 960 | 35.4 % | ||
Others | 6 278 | 2.5 % | 8 504 | 3.5 % | - 2 226 | - 26.2 % |
Gross profit | 87 817 | 34.4 % | 65 448 | 26.8 % | 22 370 | 34.2 % |
Operating profit | 39 888 | 15.6 % | 19 445 | 8.0 % | 20 442 | 105.1 % |
thereof continued business group | 39 888 | 15.6 % | 16 611 | 6.8 % | 23 276 | 140.1 % |
Financial income | 2 595 | 1.0 % | 2 341 | 1.0 % | 253 | 10.8 % |
Financial expenses | - 4 219 | - 1.7 % | - 5 048 | - 2.1 % | 829 | - 16.4 % |
Income taxes | - 1 684 | - 0.7 % | - 1 300 | - 0.5 % | - 384 | 29.5 % |
Net profit | 36 579 | 14.3 % | 15 439 | 6.3 % | 21 141 | 136.9 % |
Earnings per share in CHF | 2.68 | 1.17 | 1.51 | 129.5 % | ||
Operating profit | 39 888 | 15.6 % | 19 445 | 8.0 % | 20 442 | 105.1 % |
Depreciation and impairment of fixed assets | 20 541 | 19 865 | 676 | 3.4 % | ||
Amortisation and impairment of intangible assets | 15 403 | 17 573 | - 2 170 | - 12.3 % | ||
EBITDA (operating profit before depreciation | 75 832 | 29.7 % | 56 883 | 23.3 % | 18 948 | 33.3 % |
and amortisation) | ||||||
Equity ratio in % | 61.2 % | 65.2 % 1 | - 4.0 % | |||
Investments in fixed assets | 51 137 | 54 645 | - 3 508 | - 6.4 % | ||
Investments in intangible assets | 39 500 | 28 310 | 11 190 | 39.5 % | ||
Number of employees | 2 231 | 2 059 1 | 172 | 8.4 % | ||
Number of full-time positions | 2 143 | 1 978 1 | 164 | 8.3 % | ||
Turnover at group level | EBIT at group level |
177.9 44.7 222.6 | 205.9 38.4 244.2 | 255.4 | 19.4 | 39.9 39.9 | |||
Ypsomed group | 2.8 | ||||||
first half-year | 6.7 3.8 10.5 | 16.6 | |||||
million CHF | Contribution DiaExpert GmbH | million CHF | |||||
first half-year 2 | |||||||
Contribution continued | |||||||
In | business first half-year | In | |||||
2021/ 22 | 2022/ 23 | 2023/ 24 | 2021/ 22 | 2022/ 23 | 2023/ 24 |
- As per 31 March 2023.
- DiaExpert GmbH divested as per 31 December 2022.
Ypsomed group first half-year
Contribution DiaExpert GmbH first half-year 2
Contribution continued business first half-year
Further information on significant shareholders and shareholder groups as well as other financial figures of the Ypsomed Group are available in the Semiannual Report 2023/24 and on www.ypsomed.ch.
Ypsomed - Investor Fact Sheet 2
Diabetes Care
With its mylife™ Diabetescare brand, Ypsomed operates
successfully in the B2C business with products and ser- mylife™ product portfolio (selection) vices for people with diabetes mellitus. The product port-
folio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed's subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).
Delivery Systems
Our pharmaceutical and biotech customers purchase in-
jection systems and corresponding services under the YDS product portfolio (selection) YDS brand, Ypsomed Delivery Systems. They do this via
the industry leader, as Ypsomed is the world's largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.
Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's dis- ease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.
Legal disclaimer: The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG, its advisors or representatives, nor their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future re- sults, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.
Ypsomed Holding AG
Thomas Kutt, Head Investor Relations // Brunnmattstrasse 6 // 3401 Burgdorf // +41 34 424 35 55 // thomas.kutt@ypsomed.com // www.ypsomed.ch
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ypsomed Holding AG published this content on 15 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2023 06:03:00 UTC.
